![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Division of Molecular Neurobiology, Department of Physiological Sciences (D.S.K., C.G., L.M.F.L.-L.) and Division of Molecular Pathogenesis, Department of Cell and Molecular Biology (M.M.), Lund University, Lund, Sweden
The human B1 bradykinin receptor is an inducible and constitutively active G protein-coupled receptor that is involved in the inflammatory and pain responses to injury. Here, we investigated the role of B1 receptor homo-oligomerization in cell surface receptor expression. B1 receptors tagged with either the FLAG or hemagglutinin epitope were monitored immunologically and by radio-ligand binding, biotinylation, and phosphoinositide hydrolysis in human embryonic kidney 293 cells. Selective immunoprecipitation, immunoblotting, and immunoelectron microscopy with epitope-specific antibodies together provided evidence for constitutively formed cell surface receptor homo-oligomers. Truncation of the receptor from the N- and C-terminal ends indicated that the epitope for oligomerization seems to be located between Leu26 on top of transmembrane helix 1 and Val71 at the bottom of helix 2. A receptor construct terminating at Asp134 at the bottom of helix 3, B1stop135, was expressed in the cell. It is interesting that this construct behaved as a dominant-negative mutant by competitively preventing formation of intact B1 receptor homo-oligomers, and redistributing B1 receptors from the cell surface to a common intracellular compartment. In contrast, expression of a construct containing the residues downstream of Asp134, B1del(2-134), was inactive in this regard. Together, these results are consistent with a mechanism where constitutive B1 receptor homooligomerization is required for expression of receptors on the cell surface and subsequent constitutive receptor signaling. This may be a novel mechanism by which the cell regulates the presentation of this constitutively highly active receptor at various stages of injury.
Address correspondence to: Dr. L. M. Fredrik Leeb-Lundberg, Division of Molecular Neurobiology, Wallenberg Neuroscience Center, BMC, A12, Sölvegatan 17, SE-22184 Lund, Sweden. E-mail: fredrik.leeb-lundberg{at}mphy.lu.se
This article has been cited by other articles:
![]() |
X. Zhang, F. Tan, Y. Zhang, and R. A. Skidgel Carboxypeptidase M and Kinin B1 Receptors Interact to Facilitate Efficient B1 Signaling from B2 Agonists J. Biol. Chem., March 21, 2008; 283(12): 7994 - 8004. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ehrenfeld, C. Millan, C. E. Matus, J. E. Figueroa, R. A. Burgos, F. Nualart, K. D. Bhoola, and C. D. Figueroa Activation of kinin B1 receptors induces chemotaxis of human neutrophils J. Leukoc. Biol., July 1, 2006; 80(1): 117 - 124. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Fortin, E. K. Dziadulewicz, L. Gera, and F. Marceau A Nonpeptide Antagonist Reveals a Highly Glycosylated State of the Rabbit Kinin B1 Receptor Mol. Pharmacol., April 1, 2006; 69(4): 1146 - 1157. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77. [Abstract] [Full Text] [PDF] |
||||